PD-1 Inhibitor Tislelizumab maintenance therapy

DRUG2 trials

Sponsors

Ruijin Hospital

Conditions

ChemotherapyLymphoma, Large B-Cell, DiffuseTransplantation

Phase 3

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Ruijin HospitalChemotherapy, Lymphoma, Large B-Cell, Diffuse, Transplantation

Start: 2021-07-09End: 2024-07-01Target: 94Updated: 2021-11-22

PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Ruijin HospitalChemotherapy, Lymphoma, Large B-Cell, Diffuse, Transplantation

Start: 2021-04-01End: 2024-04-01Target: 132Updated: 2021-03-16

Related Papers

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

Blood2025-11-03